Press Release: Novartis RemIND data at EAACI show -2-

Novartis

132.64 EUR -0.27%

• Charts
• News
• Analysen

Kaufen Verkaufen

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Mosnaim G, Giménez-Arnau A, Ensina LF, et al. Remibrutinib

demonstrated superior efficacy vs placebo and favorable safety in

patients with chronic inducible urticaria in the phase 3 REMIND study.

Presented as a late abstract at EAACI 2026; June 12-15, 2026; Istanbul,

Türkiye. Abstract number 100213

2. Data on files

3. Maurer M, et al. How to approach Chronic Inducible Urticaria, The Journal

of Allergy and Clinical Immunology, 2018, Volume 6, Issue 4, Pages

1119-1130

4. World Population Prospects, Department of Economic and Social Affairs

Population Division, United Nations. Available from:

https://population.un.org/wpp/downloads?folder=Standard%20Projections&group=Population

[Last accessed: February 2026]

5. Pereira ARF, et al. Einstein (Sao Paulo). 2020;18:eAO5175.

6. Kocatürk E, et al. J Dermatol Sci. 2017;87(1):60-69

7. Mosnaim G, Giménez-Arnau A, Ensina LF, et al. Remibrutinib

demonstrated superior efficacy vs placebo and favorable safety in

patients with chronic inducible urticaria in the phase 3 REMIND study.

Presented at a late oral abstract session L-OAS03 at EAACI 2026; June

12-15, 2026; Istanbul, Türkiye. Abstract number 100213.

8. Kolkhir P, et al. Urticaria. Nat Rev Dis Primers. 2022;8(61)

9. Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel

BTK inhibitor, demonstrates promising efficacy and safety in chronic

spontaneous urticaria. J Allergy Clin Immunol 2022; 150: 1498-1506.

10. Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib),

a potent and highly selective covalent inhibitor of Bruton's Tyrosine

Kinase. J Med Chem 2020; 63: 5102-5118.

11. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of

chronic urticaria and angioedema. Clin Exp Allergy 2015; 45: 547-565.

12. Patient. Antihistamines. Last updated 12 October 2022. Available from:

https://patient.info/allergies-blood-immune/allergies/antihistamines

[Last accessed: February 2026].

13. ClinicalTrials.gov. NCT03827798. Study of efficacy and safety of

investigational treatments in patients with moderate to severe

hidradenitis suppurativa. Available

from: https://clinicaltrials.gov/ct2/show/NCT03827798. [Last accessed:

February 2026]

14. ClinicalTrials.gov. NCT05432388. Study of efficacy, safety and

tolerability of remibrutinib in adult participants with an allergy to

peanuts. Available

from: https://clinicaltrials.gov/study/NCT05432388 [Last accessed:

February 2026].

15. ClinicalTrials.gov. NCT05147220. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-1). Available

from: https://clinicaltrials.gov/study/NCT05147220 [Last accessed:

February 2026].

16. ClinicalTrials.gov. NCT05156281. Efficacy and safety of remibrutinib

compared to teriflunomide in participants with relapsing multiple

sclerosis (RMS) (REMODEL-2). Available from:

https://clinicaltrials.gov/study/NCT05156281 [Last accessed: February

2026].

17. ClinicalTrials.gov. NCT05976243. A Study to Investigate Efficacy, Safety,

and Tolerability of Remibrutinib Compared With Placebo in Adults With

CINDU Inadequately Controlled by H1-antihistamines. Available from:

https://clinicaltrials.gov/study/NCT05976243 [Last accessed: February

2026].

18. Pozderac I, et al. Chronic inducible urticaria: classification and

prominent features of physical and non-physical types. Acta

Dermatovenerol Alp Pannonica Adriat. 2020;29(3):141--8

19. Zuberbier et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI

guideline for the definition, classification, diagnosis and management of

urticaria. Allergy.2022;77(3):734--66

20. M Kern B, et al. Physician estimation of the prevalence and clinical

impact of chronic urticaria: results of the global, multicenter UCARE

CU-PAPER study, Frontiers in allergy, 2026, volume 6:1732893

21. Munoz M, et al. New insights into chronic inducible urticaria. Current

Allergy and Asthma Reports, 2024 volume 24, 457-469

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 12, 2026 05:36 ET (09:36 GMT)